Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: Retrospective analysis of patient data from five clinical trials

Preetesh Jain, Hagop Kantarjian, Mona Lisa Alattar, Elias Jabbour, Koji Sasaki, Graciela Nogueras Gonzalez, Sara Dellasala, Sherry Pierce, Srdan Verstovsek, William Wierda, Gautam Borthakur, Farhad Ravandi, Susan O'Brien, Jorge Cortes

Research output: Contribution to journalArticle

46 Scopus citations

Fingerprint Dive into the research topics of 'Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: Retrospective analysis of patient data from five clinical trials'. Together they form a unique fingerprint.

Medicine & Life Sciences